Blood clots are ‘incredibly common,’ even for pro athletes like Jalen Hurts. Here’s what to know.

The revelation that blood clots are a common issue even among professional athletes like Jalen Hurts highlights the significant health risks associated with deep-vein thrombosis and pulmonary embolism. For the fund industry, this raises important considerations regarding the long-term health and career prospects of athletes, which can have implications for investments in sports-related assets or sponsorships. The fact that recovery can take over six months underscores the potential for substantial downtime and lost revenue.

The lengthy recovery period for athletes suffering from blood clots also has broader implications for the sports industry as a whole. Investors and funds with stakes in professional sports teams or leagues may need to reassess their risk management strategies to account for the potential impact of such health issues on team performance and player availability. Furthermore, the prevalence of blood clots among athletes may lead to increased investment in medical research and development of new treatments, presenting opportunities for funds focused on healthcare and biotechnology.

As the sports and finance industries continue to intersect, it will be important to monitor how teams, leagues, and investors respond to the risks posed by blood clots and other health issues affecting professional athletes. Funds with exposure to the sports sector should watch for developments in medical research and treatment options, as well as changes in risk management practices and athlete support services. Additionally, investors should be aware of the potential for increased investment in healthcare and sports medicine, which could present new opportunities for growth and returns.

Originally reported by marketwatch.com. FundNews adds analysis for finance & markets readers.